David L Sloman

USPTO Granted Patents = 34 (Patent Applications = 9)

CIPO Patents = 1

EPO Patents = 22 (Patent Applications = 32)

Average Co-Inventor Count = 10.1

ph-index = 5

Forward Citations = 91(Granted Patents)

Location History:

Boston, MA (US) (2009 - 2019)
Brookline, MA (US) (2014 - 2022)
Newton, MA (US) (2021 - 2024)

Company Filing History:

33 out of 2,405

Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

patents

4. 1 out of 7

Msd International Gmbh

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

34 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12441730 - PRMT5 inhibitors (2025-10-14),

2. 12297208 - Small molecule inhibitors of KRAS G12C mutant (2025-05-13),

3. 12291538 - Small molecule inhibitors of KRAS G12C mutant (2025-05-06),

4. 12275729 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-14),

5. 12215116 - Arginase inhibitors and methods of use (2025-02-04),

6. 12173026 - PRMT5 inhibitors (2024-12-24),

7. 12091405 - Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2024-09-17),

8. 12065438 - Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors (2024-08-20),

9. 11697657 - Small molecule inhibitors of KRAS G12C mutant (2023-07-11),

10. 11274111 - Arginase inhibitors and methods of use (2022-03-15),

11. 11208407 - Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-12-28),

12. 11098059 - PRMT5 inhibitors (2021-08-24),

13. 10995085 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-05-04),

14. 10975084 - KDM5 inhibitors (2021-04-13),

15. 10647705 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2020-05-12),

Title: The Innovative Contributions of David L. Sloman

Introduction: David L. Sloman, based in Brookline, MA, is a prolific inventor with 30 patents to his name. His work has significantly impacted the pharmaceutical industry, particularly in the development of novel therapeutic agents.

Latest Patents: Among his most recent patents are two groundbreaking inventions. The first, titled "Arginase Inhibitors and Methods of Use," details compounds of Formula I, which serve as arginase inhibitors that can aid in preventing and treating arginase-related diseases. His second patent, "PRMT5 Inhibitors," introduces a compound of Formula I, alongside its pharmaceutically acceptable salts, esters, and prodrugs. This invention offers methods for treating conditions such as cancer and specific genetic mutations, demonstrating the broad therapeutic potential of his work.

Career Highlights: David has made considerable strides in his career, having worked with prominent companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His contributions in these roles reflect a deep commitment to advancing healthcare through innovation.

Collaborations: Throughout his career, Sloman has collaborated with notable colleagues, including David James Witter and Matthew G. Stanton. These collaborations highlight a network of skilled professionals working towards common goals in the field of pharmaceuticals.

Conclusion: David L. Sloman's impressive portfolio of patents and collaborations demonstrates his significant contributions to modern medicine. His innovative spirit continues to inspire progress in the treatment of complex diseases, underscoring his role as a leading inventor in the pharmaceutical realm.

This text is generated by artificial intelligence and may not be accurate.